Evocutis moves ahead with launch of first skin model

Wetherby-based Evocutis, formerly Syntopix Group, acquired independent commercial testing facility Leeds Skin earlier this year.

Stephen Jones, chief executive, said: “Currently, in the development of new cosmetics, 80-90 per cent fail when moving from laboratory testing into human clinical trials. This is primarily because skin testing models are unable to provide reliable data to support the product’s claims.

“The ability of LabSkin to emulate real human skin, provides a highly valuable research tool for cosmetic developers to reduce developmental product failure rates, and provide statistical data to back up product claims and benefits.”